Circio and NeoRegen Biotech proceed to in vivo, transferring circular RNA biotech to gene, cell therapy and targeted drug delivery.

To further its biotech cooperation, Circio Holding ASA and NeoRegen Biotech have entered into their second Material Transfer Agreement (MTA) taking the relationship into the in vivo preclinical phase. It comes after biopharmaceutical company Acalabrutinib and their initial 2023 contract proved successful in vitro.

Its collaboration is targeted at addressing major hands-on issues regarding the delivery of nucleic acids in medicine. The circVec platform developed by Circio that uses circular RNA as an expression system will be integrated with the proprietary technology (NICT (Neoregen Intra-Cellular Delivery Technology) of NeoRegen Biotech in the effort to make treatments with it more durable and targetable.

It is a critical biotech milestone, as the research product has moved on to the in vivo phase, according to Dr. Jeongmin Seo, CEO of NeoRegen. "There is high potential for our NICT platform with the circVec of Circio in gene and cell therapies."

Dr. Thomas Hansen, CTO of Circio said, "This development has shown that NeoRegen Biotech has the faith to test circVec DNA vectors on living models. Our goal is to select areas of interest in diseases and progress rapidly towards clinical development.”

The two biotech companies are today aiming at safe, efficient, and lasting intracellular delivery of DNA-format therapeutics. The shared work has biomedical potential in oncology and gene therapy as well.

Through this second MTA, Circio and NeoRegen prove again their intention to transform the system of biotech deliveries, and sooner or later expect it to be clinically ready, brought up by the superior R&D program.